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 Abstract 
 Objective: The purpose of this study is to compare the safety 
and effi cacy of intravenous (IV) high-dose iron carboxymalt-
ose (ICM) with iron sucrose (IS) for the treatment of postpar-
tum anemia. 
 Study design: We performed a retrospective cohort study with 
210 anemic inpatient women in the postpartum period who 
received IV high-dose ICM (15 mg/kg; maximum, 1000 mg) 
or IS (2 × 200 mg), respectively. Safety and tolerability of both 
groups were compared on the basis of reported systemic and 
local adverse events. The cohorts were matched for baseline 
characteristics and their initial hemoglobin (Hb) values. The 
secondary endpoint included drug effi cacy assessment by mea-
surement of Hb level increase up to 8 days after treatment. 
 Results: Rapid administration of high ICM doses was as well 
tolerated as IS with overall adverse events of 5 % (ICM) vs. 
6 % (IS). The most common complaint was burning and pain 
at the injection site. ICM was as effective as IS in changing 
Hb levels from the baseline. There was no difference in the 
mean daily Hb increase between the groups. Women with 
severe anemia showed the most effective responsiveness. 
 Conclusions: IV ICM is as safe as IS in the management of 
postpartum (IDA) iron defi ciency anemia despite fi ve times 
of higher dosage. Both drugs are effective and offer a rapid 
normalization of Hb after delivery. The single application of 
ICM shows advantages of lower incidence of side effects at 
the injection site, a shorter treatment period, and better patient 
compliance. 
 Keywords:  Ferinject  ®  ;  hemoglobin;  iron carboxymaltose; 
 iron sucrose;  parenteral iron substitution;  Venofer  ®  postpar-
tum anemia. 
 Introduction 
 The World Health Organization defi nes anemia as a hemoglo-
bin (Hb)  < 120 g/L in women and 130 g/L in men. For children 
and pregnant women, the limit is set by 110 g/L  [3, 4, 9, 24, 
25, 31] . In developed countries, anemia is often found among 
children and pregnant women. Their iron requirement makes 
these groups more vulnerable to the typical iron defi ciency 
anemia (IDA) with hypochromic, microcytic erythrocytes and 
low ferritin values  [7, 25] . Data from the National Health and 
Nutrition Examination Survey  [8] indicate that IDA is preva-
lent in 4.2 % of all postpartum US women aged 20 – 40 years. 
 Iron defi ciency is the most common cause of anemia  [3, 4, 9, 
13, 24, 31] and is associated with a variety of coexisting condi-
tions. Its general health effects include various symptoms such 
as fatigue, headaches, dizziness, breathlessness, palpitations, 
reduced cognitive functions, and depression  [6, 9, 24, 34] . 
 Postpartum IDA is caused primarily by inadequate iron 
intake before pregnancy and by peripartum blood loss 
 [31, 35] . It affects low-income and minority women dispro-
portionately  [5, 7, 8] . It may impose a substantial disease 
burden during a critical period of maternal-infant interactions 
and can be very debilitating, especially when caring for a 
newborn  [6, 24, 31, 35] . Furthermore, anemic puerperia have 
a longer average length of hospital stay, are more likely to 
receive a blood transfusion, and incur higher hospitalization 
costs  [3, 13, 31] . Hence, postpartum IDA requires our atten-
tion and high-quality care. 
 Treatment of IDA involves identifying and treating the cause 
of the condition as well as replacing iron  [3, 24] . The most 
reliable parameter to assert postpartum IDA is Hb, because 
ferritin levels may vary and indicate false elevated values 
after delivery  [22] . The treatment depends on the severity of 
the case and the woman ’ s state of health. The recommended 
treatment for mild IDA (Hb  > 95 g/L) consists in oral admin-
istration of 80 – 200 mg of iron (II) salts or iron (III) polymalt-
ose, with the alternative of intravenous (IV) treatment in case 
of bad compliance or gastrointestinal intolerance. For more 
severe IDA (Hb  < 95 g/L), parenteral administration of iron is 
recommended  [4, 18, 25, 32] . 
 Although iron therapy is indicated in the anemia patient, 
both oral iron agents and currently available IV iron agents 
pose their challenges. Oral iron intake is limited by gastro-
intestinal complaints and patient non adherence  [1, 3, 17, 
35] . To overcome these problems, we used a number of IV 
preparations [e.g., iron dextran, sodium ferric gluconate, or 
iron sucrose (IS)]. However, the latter either require multiple 
administrations of low doses to replenish stores (sodium fer-
ric gluconate and IS) or are associated with hypersensitivity 
reactions (iron dextran, 1.2 % )  [1, 17, 24, 35] . 
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 Therefore, responding to the need for a novel preparation 
able to rapidly replenish iron stores with large iron doses and 
minimal risks of hypersensitivity or other adverse effects, 
iron carboxymaltose (ICM) (Ferinject  ®  ) was developed and 
approved in 2008 as new IV treatment option in the majority 
of European countries  [22] . 
 The safety and effi cacy of ICM in the treatment of postpar-
tum IDA have been tested in a number of randomized, multi-
center studies  [3, 4, 6, 13 – 17, 23, 29, 31 – 35] . It was always 
compared with oral iron agents and demonstrated an outstand-
ing safety profi le combined with good effectiveness. ICM 
overcame the gastrointestinal limitations of oral treatment. 
Furthermore, through single administration, it offered many 
practical benefi ts such as greater patient comfort and compli-
ance, shorter hospitalization time, and fi nally, cost reduction. 
 With the exception of one trial in chronic kidney patients 
undergoing hemodialysis  [20] , comparative trials of ICM and 
other IV formulations are still lacking. The aim of the current 
study was therefore to compare two IV iron agents, ICM and 
IS, for the treatment of postpartum anemia. The choice of IS 
as comparator was made because of its general acceptance as 
standard of care in the treatment of postpartum IDA. Based on 
the results of the above-quoted studies, we hypothesized that 
ICM is as safe and tolerable as IS despite fi ve times of higher 
dosage. Even though the schedule foresees a single applica-
tion of ICM, we assume that the hematologic responsiveness 
equals the one induced by IS. 
 Material and methods 
 Study design and population 
 This retrospective, exploratory cohort study was conducted at the 
University Women ’ s Hospital in Bern, Switzerland. A total of 210 
patients with postpartum IDA requiring IV iron supplementation 
were included. The inclusion criteria were women with an Hb  < 95 
g/L (n = 200, 95.23 % ), anemic patients with  > 95 g/L and intolerance 
of oral iron medication, insuffi cient Hb increase after oral treatment, 
or need to replenish iron stores rapidly. To assure statistical compa-
rability, we matched the two arms of the study population as regards 
demographic baseline characteristics Hb value at baseline and con-
founders such as severe birth complications (preeclampsia/HELLP) 
and additive therapies [erythropoietin, blood transfusion, fresh frozen 
plasma (FFP)]. The Hb values before therapy were 81.98 ± 10.91 g/L 
in the ICM cohort and 80.11 ± 10.3 g/L in the IS arm, respectively 
(P = 0.19). Thus, we enrolled 105 women treated with ICM (15 mg/
kg; maximum, 1000 mg over 15 min, almost all women receiving the 
maximum dose) over the years 2008 – 2010. The comparative group 
comprised 105 women who had received IS (2 × 200 mg at 2 days ’ in-
terval) in the years 2005 – 2008 before introduction of ICM in clinical 
routine care. All women with a history of anemia other than iron defi -
ciency or blood loss were excluded (e.g., vitamin B12/folate-defi ciency 
anemia, hemoglobinopathy, hemolytic anemia, tumor anemia). 
 In our inpatient postpartum study population, the primary outcome 
was to assess safety and tolerability of ICM compared with IS on the 
basis of adverse events that were spontaneously reported, elicited, 
or observed by the nurse or midwife during or after administration 
of the study drug. The routine clinical treatment protocol includes 
surveillance of the patient during and after IV iron administration 
and meticulous documentation of any abnormal signs or symptoms. 
Therefore, despite the retrospective design, we assume the most reli-
able reports of adverse events by the medical staff, because IV iron 
infusions are closely documented on a specifi c monitoring sheet. Our 
secondary outcome included the record of Hb increase from baseline 
from onset of the treatment up to dismissal of the patients (maxi-
mum, 8 days). In each of the study groups, two cases with follow-up 
data after a surveillance of a maximum of 47 and 60 days, respec-
tively, were also enclosed. 
 In order to assess potential effects of the study drug in particu-
lar clinical conditions, subgroup analysis was carried out on patients 
with peripartum complications (preeclampsia/HELLP syndrome or 
severe postpartum hemorrhage with Hb  < 75 g/L) or receiving addi-
tional therapy to the iron supplementation [allogeneic blood transfu-
sion/FFP or erythropoiesis-stimulating agent (ESA)]. 
 Statistical analysis 
 All subgroups passed the normality test, thus allowing a statistical 
correct matching of the study participants, despite the restricted num-
ber (e.g., in the substudy preeclampsia/HELLP syndrome). We espe-
cially checked for compatibility of baseline Hb of the two cohorts 
previous to treatment using the two-tailed Mann-Whitney  U -test. 
Passing this normality test was the reason for setting the limit to 75 
g/L in the substudy with severe anemia women. In the analysis of our 
safety endpoint, we compared categorical variables of adverse events 
using the two-sided Fisher ’ s exact test, which we preferred over the 
 χ 2 -test because of the small number of reported adverse events. To 
assess for effi cacy, we verifi ed the statistical signifi cance of between-
group differences in Hb increase by applying the unpaired Welch-
corrected  t -test (two-tailed P-value) for continuous parameters. For 
all analyses, P-values  < 0.05 were considered statistically signifi cant. 
All tests were executed using the software programs Excel and Graph 
Pad InStat for Microsoft software, Inc., La Jolla, CA, USA. 
 Results 
 Demographic and clinical characteristics of the study partici-
pants are displayed in Table  1 . No major differences between 
the groups were detected. 
 Tolerability 
 Both ICM and IS were very well tolerated, with an overall 
incidence of drug-related adverse events of 4.8 % in the ICM 
and 5.7 % in the IS group (Table  2 ). Most of them were mild to 
moderate. The highest incidence was registered in local burn-
ing and pain at the infusion site (1.9 % vs. 3.8 % ). 
 Three patients of the ICM group experienced systemic 
manifestations such as headache, sensation of heat, and short 
shivering. However, blood pressure remained normal, and 
there was no sign of anaphylaxis. In the IS group, one patient 
complained about fatigue and one about alteration of taste. 
The between-group difference was not statistically signifi cant. 
No severe safety concern (e.g., hypersensitivity, anaphylaxis) 
occurred in either treatment groups. 
 Effi cacy 
 The response rates of Hb are listed in Table  3 . In the ICM 
group, the mean Hb levels increased from 81.9 g/L at baseline 
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to 92.2 g/L after an average control interval of 4.3 days. In the 
IS population, it increased from 80.1 g/L to 88.2 g/L after 3.9 
days. The calculated daily increase was 3.3 g/L and 4.1 g/L, 
respectively. There was no between-group difference in terms 
of absolute or daily Hb changes (P = 0.26 and P = 0.89). 
 Graphic  1 illustrates the course of Hb response rate at the 
time point of 2, 5, and 8 days. In an initial phase, both groups 
showed great effectiveness (5.1 vs. 6.9 g/L after only 2 days); 
at longer interval, however, ICM seemed to have a better and 
presumably more sustained effect on the hemoglobin value 
compared with IS (14.9 vs. 11.7 g/L after 5 days, 18.3 vs. 
5.3 g/L after 8 days). Although absolute values went further 
apart the longer the interval from the onset of therapy, these 
between-group differences were not statistically signifi cant at 
any time point (P = 0.26 by 2 days, P = 0.38 by 5 days, P = 0.1 







Hb before therapy (g/L)
  Mean ± SD 81.9 ± 10.9 80.1 ± 10.0 0.19
  Range 50 – 110 48 – 96
Age (years)
  Mean ± SD 30.5 ± 6.2 32.0 ± 5.3 0.65
  Range 16 – 43 17 – 45
Gravidity
  Mean ± SD  1.9 ± 1.1  2.0 ± 1.4 0.97
  Range  1 – 6  1 – 8
Parity
  Mean ± SD  1.7 ± 0.9  1.5 ± 1.0 0.17
  Range  1 – 5  1 – 6
Delivery method [n ( % )]
  Vaginal 31 (29.5 % ) 30 (28.6 % ) 1.00
  Cesarean 56 (53.3 % ) 58 (55.2 % ) 0.89
  Forceps  2 (1.9 % )  4 (3.8 % ) 0.68
  Vacuum 16 (15.2 % ) 13 (12.4 % ) 0.69
Confounding factors [n ( % )]
Complication of delivery
  Preeclampsia/HELLP 11 (10.5 % ) 12 (11.4 % ) 1.00
  Severe anemia 25 (23.8 % ) 24 (22.9 % ) 1.00
Additive therapy
  Erythropoietin 19 (18.1 % ) 21 (20.0 % ) 0.86
  Blood transfusion (FFP) 19 (18.1 % ) 18 (17.1 % ) 1.00






Total 5 (4.8 % ) 6 (5.7 % ) 1.00
Local pain 2 (1.9 % ) 4 (3.8 % ) 0.68
Systemic 3 (2.9 % ) 2 (1.9 % ) 1.00
 Headache 1 (0.9 % ) 0 1.00
 Sensation of heat 1 (0.9 % ) 0 1.00
 Shivering 1 (0.9 % ) 0 1.00
 Fatigue 0 1 (0.9 % ) 1.00
 Alteration of taste 0 1 (0.9 % ) 1.00
by 8 days). Beyond 8 days, the response was associated with a 
further increase in the ICM group, whereas the curve of the IS 
group remained stable. This observation refl ects a trend and 
is to be taken with caution however. The restricted number 
of patients observed at long-term did not allow for a reliable 
statistical statement. 
 Subgroup: preeclampsia/HELLP syndrome 
 Eleven and 12 patients experienced preeclampsia or fully 
developed HELLP syndrome in the ICM and IS group, 
respectively. The tolerability of these women was very good. 
Not a single adverse event was registered in either group. In 
the ICM population, the mean Hb levels increased from 81.0 
g/L at baseline to 98.9 g/L after 5.8 days. In the comparison 
group, it improved from 78.8 g/L to 87.4 g/L after 3.5 days. 
Converted on a daily rate, the rise in Hb levels was 3.2 and 3.5 
g/L a day, respectively. The between-group difference was not 
signifi cant (P = 0.75). 
 Subgroup: severe anemia 
 The criteria for a severe anemia were fulfi lled in 25 women 
treated with ICM and in 24 with IS. Two local drug reactions 
were registered in each group (8.0 % vs. 8.3 % ). The mean Hb 
raised from 67.1 g/L at baseline to 89.7 g/L after 3.9 days 
(ICM), in contrast to 65.3–81.2 g/L at an interval of 3 days 
(IS). The daily amounts were 6.0 g/L a day compared with 
6.9 g/L a day, respectively. The difference was not signifi cant 
(P = 0.54). 
 Subgroup: ESA 
 Another subcategory was formed by 19 and 21 women treated 
with ESAs in addition to the iron treatment. On 4 days, 10,000 
IE of erythropoietin were administered. The administration of 
ICM caused one local pain complaint (5.3 % ) and a short shiv-
ering episode (5.3 % ) in another woman. Application of IS did 
not provoke any drug-related reaction. This difference was 
not signifi cant (P = 0.22). A discrepancy was also observed 
regarding the therapy response. The mean Hb increased 
from 71.0 g/L to 89.1 g/L after an average of 3.7 days (18.1 
g/L) in patients treated with ICM and from 71.3 g/L to 78.9 
g/L after 2.4 days (7.6 g/L) in women receiving IS, respec-
tively (P = 0.023). This difference may be due to the uneven 
Hb-control interval. The daily increase did not let any signifi -
cant variation appear (5.0 vs. 4.6 g/L a day, P = 0.56). 
 Subgroup: blood transfusion 
 Allogeneic donor blood transfusion was administered to 19 
(ICM) and 18 (IS) women with severe clinical symptoms and 
very low Hb values. The administration dose ranged from 
1 to 14 blood units, depending on the severity of the woman ’ s 
state of health. Only one minor local pain at the infusion site 
was reported in both groups (5.6 % vs. 5.6 % ). The mean Hb 
increased from 72.7 g/L to 93.8 g/L after 3.5 days in the ICM 
group and from 68.6 g/L to 87.7 g/L after 3.4 days in the IS 
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group. Although the daily response rate was less effective in 
the ICM group (6.1 g/L a day) compared with the IS (9.4 g/L 
a day) group, it was not found to be of statistical signifi cance 
(P = 0.35). 
 Discussion 
 IV iron substitution is frequently used in the management of 
IDA postpartum. New iron preparations offer the possibility 
to treat with a large dose of IV iron in a single IV adminis-
tration. Safety and tolerability of these new preparations are 
therefore important. 
 In terms of tolerability, both ICM and IS showed a very 
low overall incidence of drug-related adverse events (4.8 % 
vs. 5.7 % , P = 1), most of them being local reactions on the 
injection site. A large number of other clinical trials con-
ducted across a wide spectrum of indications for ICM support 
the results of our current investigation  [1 – 4, 6, 13 – 19, 23, 24, 
28, 29, 30 – 35] . The overall incidence of adverse events in 
this literature was generally similar or higher than our fi nd-
ings (5.4 %  [30] , 10.6 %  [31] , 9.3 %  [3] , 26 %  [13] ), and the 
risk of hypersensitivity or other serious drug reactions was 
minimal or neglectable also. Furthermore, no safety concerns 
were identifi ed in breastfed infants of mothers receiving ICM 
 [13] . To avoid hypotension and other dose-related adverse 
reactions, we limited administration of prior available IV iron 
agents to 100 mg for iron dextran over 2 min, 125 mg of fer-
ric gluconate over 10 min, or 200 mg of IS over 2 – 5 min 
 [35] . ICM can be administered 15 mg/kg and a maximum of 
1000 mg over 15 min. Thus reducing the need for multiple 
 Table 3  Effi cacy parameter: response rates for Hb. 
ICM IS P-value
Mean ± SD Range 95 % CI Mean ± SD Range 95 % CI
Hb before therapy (g/L) 81.9 ± 10.9 50 – 110 79.8 – 84.1 80.1 ± 10.0 48 – 96 78.2 – 82.1 0.19
Hb after therapy (g/L) 92.2 ± 12.3  70 – 138 89.1 – 95.3 88.2 ± 12.1 57 – 126 85.3 – 91.2 0.09
Control interval (days)   4.3 ± 5.9  1 – 47   2.8 – 5.8   3.9 ± 7.1 1 – 60   2.2 – 5.7 0.24
Absolute Hb increase (g/L) 12.9 ± 14.3  – 11 to  50   9.3 – 16.6   9.3 ± 11.9  – 11 to  53   6.3 – 12.2 0.26



































 Graphic 1  Mean Hb deviation from baseline. 
infusions, ICM renders an ideal option for safe, rapid, and 
uncomplicated IV iron replenishment. 
 The only available trial so far  [29] comparing ICM and IS 
directly was conducted on the setting of patients undergoing 
hemodialysis. It showed a lower proportion of ICM than IS 
recipients who experienced at least one drug-related adverse 
event. 
 Based on the change of Hb, ICM and IS iron treatment 
were both effective in treating postpartum IDA. We found a 
considerable responsiveness especially during the fi rst 5 days. 
There was no signifi cant between-group difference at any reg-
istered time point. The mean daily increase was of 3.3 and 
4.1 g/L a day. 
 Our results validate several randomized, open-label, con-
trolled, multicenter trials in postpartum patients where ICM 
was considered to be very effective in the treatment of IDA, 
most of them elaborated over a long-term follow-up of 12 
weeks  [6, 13, 35] . Other publications give an overview over 
the changes of Hb levels during the fi rst few days after treat-
ment with comparable results for IS  [10, 26, 27] . 
 The clinical advantage of ICM in the treatment of postpar-
tum IDA is shown in other studies, especially when compared 
with oral treatment that did not prove to replenish iron stores 
suffi ciently  [3, 13, 31] . 
 The subgroup analysis in women with preeclampsia or 
HELLP syndrome, both with IV treatments, was associated 
with a very good tolerability and showed a similar Hb change 
compared with the overall population. No studies published 
to date on this very population were found to support our 
fi ndings. We therefore assume that both ICM and IS can be 
considered as valuable drug options in the treatment of these 
special high-risk patients. 
 Patients with severe anemia showed a good tolerability, 
and the response rate was greatest in patients with the low-
est Hb values, as reported in previous studies  [13, 31, 35] . It 
exceeded thus considerably the rate measured in the overall 
study population. IV iron replacement is most advantageous in 
such patients, where rapid availability of iron is important to 
correct anemia. Sure enough, patients with more severe IDA 
are of particular concern, because they are at higher risk of 
recurrent IDA once menstruation restarts, and the iron defi cit 
could be carried forward into subsequent pregnancies  [13] . 
 The combination of ESA and parenteral iron was well 
tolerated (overall adverse events, 10.5 % vs. 0 % , P = 0.22), 
which is supported by the results of studies combining ICM 
and ESA  [15] as well as IS and ESA  [12, 21] . In terms of 
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effi cacy, combined application showed better results than 
single iron substitution (5.0 vs. 4.6 g/L a day). We must make 
allowance, however, that this subgroup started with lower 
baseline Hb values, which can partly explain the greater 
hematologic responsiveness. In keeping with our results, it 
was demonstrated  [11] that the vicious circle encountered in 
IDA (inhibited erythropoiesis, restricted iron availability, low 
erythropoietin serum levels) can be overcome by administrat-
ing the patients a combined therapy with ESA/IV iron. Yet, 
IDA should be corrected before initiation of ESA treatment, 
because insuffi cient iron availability can lead to hyporespon-
siveness to ESA  [28] . Good assessment for safety and effi -
cacy of this combinative therapy is of great interest, because it 
is considered to be the therapeutic option in severely anemic 
women. 
 Women in need of blood transfusion with additional 
IV iron replacement showed a good tolerability, with only 
one reported injection site reaction in each group (5.6 % ). 
Although the baseline Hb was comparable with the subgroup 
with severe anemia, the response rate with additive admin-
istration of blood units or FFP did not induce a signifi cant 
greater Hb improvement (iron only, 6.0 vs. 6.9 g/L a day; iron 
and blood transfusion/FFP, 6.1 vs. 9.4 g/L a day, P = 0.35). In 
any case, either with or without blood transfusion, IV iron 
was effi cient in correcting severe anemia. In a trial by Van 
Wyck et al.  [34] with women receiving a large dose of ICM 
after heavy uterine bleeding, it was even shown that a mean 
ICM dose provided the iron required to produce the equiva-
lent of fi ve units of blood. 
 Some specifi c limitations of our study should be consid-
ered. First, although the four subgroups studied ascertain a 
good tolerability and effi cacy, the small number of patients 
in the subgroups especially in women with preeclampsia/
HELLP syndrome (n = 11 vs. 12) may not offer enough statis-
tical power to reach suffi cient evidence. Second, because of 
its retrospective nature, our study did not examine the effects 
of improving hematologic parameters such as ferritin or 
transferrin saturation, nor did it follow the women over a very 
longer period to assess for possible delayed adverse events 
or signifi cant long-term changes in Hb response. Prospective 
trials will be required to confi rm whether the presumed higher 
iron stores achieved in IV ICM-treated patients imply a per-
sistent treatment benefi t in women with ongoing menses or 
subsequent pregnancy. 
 Conclusion 
 Iron defi ciency anemia postpartum results in a considerable 
disease burden. The rapid correction of IDA is of particular 
interest in severe anemic women declining the need for blood 
transfusions. 
 Our fi ndings and the above-mentioned reports show 
robust evidence of safety and tolerability of IV high-dose 
iron supplementation with ICM postpartum. Our data fur-
ther show that ICM has the same effi cacy and safety profi le 
in high doses as compared with other IV iron formulations, 
without the inconvenience of multiple small-dose injections. 
High-dose ICM should be the treatment of choice if IV iron 
treatment is indicated in postpartum anemia. 
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